Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease EB Swallow, D Reyes, NS Hopkinson, WDC Man, R Porcher, EJ Cetti, ... Thorax 62 (2), 115-120, 2007 | 904 | 2007 |
Unliganded progesterone receptor-mediated targeting of an RNA-containing repressive complex silences a subset of hormone-inducible genes GP Vicent, AS Nacht, R Zaurin, J Font-Mateu, D Soronellas, F Le Dily, ... Genes & development 27 (10), 1179-1197, 2013 | 89 | 2013 |
First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases A Borroto, D Reyes-Garau, MA Jiménez, E Carrasco, B Moreno, ... Science translational medicine 8 (370), 370ra184-370ra184, 2016 | 52 | 2016 |
Co-evolution of the branch site and SR proteins in eukaryotes M Plass, E Agirre, D Reyes, F Camara, E Eyras Trends in genetics 24 (12), 590-594, 2008 | 51 | 2008 |
Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma M Gonzalez-Santamarta, G Quinet, D Reyes-Garau, B Sola, G Roué, ... Proteostasis and Disease: From Basic Mechanisms to Clinics, 153-174, 2020 | 37 | 2020 |
Pharmacological targeting of BET bromodomain proteins in acute myeloid leukemia and malignant lymphomas: from molecular characterization to clinical applications D Reyes-Garau, ML Ribeiro, G Roué Cancers 11 (10), 1483, 2019 | 36 | 2019 |
Activation of mitogen-and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins D Reyes, C Ballaré, G Castellano, D Soronellas, JR Bagó, J Blanco, ... Oncogene 33 (12), 1570-1580, 2014 | 32 | 2014 |
R-Ras2 is required for germinal center formation to aid B cells during energetically demanding processes P Mendoza, N Martínez-Martín, ER Bovolenta, D Reyes-Garau, ... Science signaling 11 (532), eaal1506, 2018 | 30 | 2018 |
Recent advances in the targeting of epigenetic regulators in B-cell non-Hodgkin lymphoma ML Ribeiro, D Reyes-Garau, M Armengol, M Fernández-Serrano, G Roué Frontiers in genetics 10, 477950, 2019 | 25 | 2019 |
Antitumor activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling in patients with B-cell non–Hodgkin lymphoma ML Ribeiro, D Reyes-Garau, M Vinyoles, N Profitós Pelejà, JC Santos, ... Clinical Cancer Research 27 (23), 6591-6601, 2021 | 11 | 2021 |
NFAT5 amplifies antipathogen responses by enhancing chromatin accessibility, H3K27 demethylation, and transcription factor recruitment G Lunazzi, M Buxade, M Riera-Borrull, L Higuera, S Bonnin, ... The Journal of Immunology 206 (11), 2652-2667, 2021 | 9 | 2021 |
PS1310 the novel bispecific CD47-CD19 antibody TG-1801 potentiates the activity of UBLITUXIMAB-UMBRALISIB (U2) drug combination in preclinical models of B-NHL ML Ribeiro, E Normant, DR Garau, HP Miskin, P Sportelli, MS Weiss, ... HemaSphere 3 (S1), 598, 2019 | 9 | 2019 |
The ublituximab-umbralisib (U2) drug regimen potentiates the activity of the novel CD47-CD19 bispecific antibody, TG-1801, through the activation of the G protein-coupled … E Normant, ML Ribeiro, N Profitos-Peleja, P Blecua, D Reyes-Garau, ... Blood 138, 1196, 2021 | 8 | 2021 |
Constitutive activation of p62/Sequestosome-1-mediated proteaphagy regulates proteolysis and impairs cell death in bortezomib-resistant mantle cell lymphoma G Quinet, W Xolalpa, D Reyes-Garau, N Profitós-Pelejà, M Azkargorta, ... Cancers 14 (4), 923, 2022 | 6 | 2022 |
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy ML Ribeiro, N Profitós-Pelejà, JC Santos, P Blecua, D Reyes-Garau, ... Frontiers in immunology 14, 1130052, 2023 | 1 | 2023 |
Safety and efficacy of EZH2 and BRD4 dual targeting in EZH2Y641mut germinal centre-derived lymphoma A Chamorro-Jorganes, ML Ribeiro, N Profitos-Peleja, D Reyes-Garau, ... Cancer Research 80 (16_Supplement), 2925-2925, 2020 | 1 | 2020 |
TG-1701, a novel irreversible Bruton’s kinase (BTK) inhibitor, cooperates with ublituximab-driven ADCC and ADCP in in vitro and in vivo models of ibrutinib-resistant mantle … ML Ribeiro, M Armengol, M Vinyoles, D Reyes-Garau, ... Immunology, 2205-2205, 2020 | 1 | 2020 |
Quadriceps strength predicts mortality in patients with chronic obstructive pulmonary disease D Reyes, EB Swallow, E Cetti, A Moore, NS Hopkinson, M Khan, ... Thorax 60, II49-II49, 2005 | 1 | 2005 |
GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activity ML Ribeiro, N Profitós-Pelejà, JC Santos, P Blecua, DR Garau, ... bioRxiv, 2022.03. 31.486558, 2022 | | 2022 |
Antitumoral activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling and improvement of anti-CD20 therapy in B-cell non-Hodgkin lymphoma ML Ribeiro, D Reyes-Garau, M Vinyoles, NP Pelejà, JC Santos, ... Hematological Oncology 39, 2021 | | 2021 |